An end to cancer gets closer

A holy grail of cancer research is about to enter human trial in 2014. A newly developed antibody that blocks a protein called CD47 allows macrophages to do the detective work need to inform killer T-cells to perform signature strikes on cancer cells.

The CD47 protein acts like a smoke screen preventing the macrophages from taking samples to report the threat of cancer cells.

See also
   New York Post